Trovagene's Onvansertib Shows Response In Phase Ib AML Study
Zacks Investment Research | Sep 19, 2019 10:51PM ET
Trovagene, Inc. (NASDAQ:TROV) announced successful completion of a phase Ib dose escalation study evaluating its sole pipeline candidate, onvansertib, in combination with standard-of-care chemotherapy for treating acute myeloid leukemia (“AML”). The company also announced that it has initiated enrolment in the phase II portion for the candidate in a similar indication.
The phase Ib study evaluated onvansertib+chemotherapy in treatment-naive patients who are ineligible for induction therapy or whose disease has relapsed following prior treatment. The study identified the recommended phase II dose of onvansertib. Data from the dose escalation phase Ib showed that onvansertib in combination with decitabine met the study’s primary endpoint of objective response rate in five out of 21 patients with difficult-to-treat relapsed/refractory AML. Moreover, 30% of the patients in the study were biomarker positive. Data also showed onvansertib plus chemotherapy was safe and well tolerated in patients. Detailed data from the study will be presented at the European Society for Medical Oncology on Sep 28.
The phase II study will evaluate a combination of onvansertib and decitabine in previously not treated patients who are not eligible for induction therapy or in patients whose disease has relapsed following up to one prior regimen.
So far this year, Trovagene’s shares have declined 47.3% compared with the industry ’s decrease of 1.4%.
Apart from AML, the company is also developing onvansertib in combination with other drugs for treating metastatic castration-resistant prostate cancer (mCRPC), metastatic colorectal cancer (mCRC) among others.
A phase II study is evaluating onvansertib in combination with J&J’s (NYSE:JNJ) Zytiga or prednisone in patients with mCRPC. Another phase Ib/II study is evaluating onvansertib in combination with Sanofi’s (NASDAQ:SNY) Zaltrap (Folfiri) and Roche’s (OTC:RHHBY) Avastin as a second-line treatment for mCRC with a KRAS mutation. The company also has plans to develop onvansertib in combaintion with AbbVie’s Venclexta for first-line AML.
In May, Trovagene signed a research collaboration agreement with Nektar Therapeutics to evaluate a combination of onvansertib and Nketar’s Onzeald BRAF and KRAS mutant colorectal cancer.
Get The News You Want
TrovaGene, Inc. Price
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.